Liaoning North Peak Pharmaceutical Co., Ltd. Liaoning North Peak Pharmaceutical Co., Ltd.

News

Company News

Industry Information

WHO official: China's drug surveillance work has achieved remarkable results

WHO official: China's drug surveillance work has achieved remarkable results

Tianjin, 15 Oct (Xinhua) -- The 37th annual meeting of the member countries of the World Health Organization's International Drug Monitoring Cooperation Program was held in Tianjin on 15 October. During the meeting, Shang Ti, head of the WHO Drug Safety and Vigilance Team, said that China has made remarkable progress in the monitoring of adverse drug reactions and has made important contributions to international cooperation in this field.

02

2023

/

03

China plans to amend 26 laws, including the Drug Administration Law

China plans to amend 26 laws, including the Drug Administration Law

Beijing, 20 Apr (Xinhua) -- This reporter learned from the 14 th meeting of the Standing Committee of the 12 th National People's Congress [NPC], which opened on 20 April, that China intends to revise 26 laws, including the Drug Administration Law, to promote the streamlining of administration and delegating power according to law. Entrusted by the State Council, Song Dahan, director of the Legislative Affairs Office of the State Council, explained the "Amendment (Draft) to 26 Laws including the Drug Administration Law of the People's Republic of China" at the meeting on the 20th, in accordance with the decision on canceling and adjusting administrative examination and approval items and other matters promulgated by the State Council three times in July, October 2014 and February 2015, and the spirit of the "Work Plan for Accelerating Price Reform in the Near Future" deliberated and adopted by the 69th executive meeting of the State Council in November 2014. The relevant legal amendments include amendments to the legal provisions related to the proposed abolition of administrative examination and approval items, amendments to the legal provisions related to the proposed decentralization of administrative examination and approval items, amendments to the legal provisions related to the proposed change of pre-approval items for industrial and commercial registration, and amendments to legal provisions related to price reform.

02

2023

/

03

China will build a new health service system of traditional Chinese medicine

China will build a new health service system of traditional Chinese medicine

Beijing, 11 Jan (Xinhua) -- This reporter learned from the State Administration of Traditional Chinese Medicine on 11 January that on the basis of in-depth implementation of the health project of "treating diseases before they occur" in traditional Chinese medicine, China will promote the development of traditional Chinese medicine health tourism, traditional Chinese medicine health pension, and traditional Chinese medicine service trade, and build a new health service system of traditional Chinese medicine. Wang Guoqiang, deputy director of the National Health and Family Planning Commission and director of the State Administration of Traditional Chinese Medicine, said at the National Traditional Chinese Medicine Work Conference held here that in the past five years of participating in the deepening of medical reform, the accessibility and accessibility of traditional Chinese medicine services have been significantly improved, and new contributions have been made to serving the people.

02

2023

/

03

Commentary: It is timely to accelerate the reform of pharmaceutical approval

Commentary: It is timely to accelerate the reform of pharmaceutical approval

Beijing, 18 Aug (Xinhua) -- Against the background of comprehensively deepening reform and streamlining administration and delegating power, the State Council issued the "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices," which released a strong signal to streamline administration and delegate power in the pharmaceutical field to accelerate the reform of the examination and approval system. In recent years, China's pharmaceutical industry has developed rapidly, but due to problems such as low drug approval standards, backward management methods, and unreasonable institutional mechanisms, many drugs that need to be approved for approval for review have accumulated for a long time, making patients in urgent need of treatment and pharmaceutical companies submitted for review dissatisfied. The data shows that there are more than 20,000 backlogs waiting for review and approval in the National Drug Evaluation Center, and there is a big gap between the number of drug approval reviews and the improvement of people's livelihood, people's needs and the expectations of pharmaceutical companies.

02

2023

/

03

The reform of the pharmaceutical industry focuses on stimulating innovation vitality

The reform of the pharmaceutical industry focuses on stimulating innovation vitality

While speeding up the review and approval, it is necessary to smooth the channel for innovative drugs to be included in pharmaceutical reimbursement. At the same time, relevant departments should encourage enterprises to increase investment in research and development and improve the standards and quality of drugs The State Council recently issued the "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices", which clarified 12 reform tasks. As the first major adjustment of the review and approval system of China's pharmaceutical industry in the past five years, this reform not only solves the problem of a large backlog of new drug applications that has been criticized, but also focuses on improving drug evaluation standards, achieving drug safety, effectiveness and quality controllability, and promoting the structural adjustment and transformation and upgrading of China's pharmaceutical industry. Some insiders pointed out that "slow" has become the biggest feature of China's current drug and medical device review and approval system. The long approval cycle has caused a serious imbalance between the number of drug registration applications and the number of approved documents, and many new drugs are blocked on the road to approval, unable to form economic and social benefits.

02

2023

/

03

< 1 >